Cardiac amyloidosis (CA) is generally accounted for by 2 subtypes: transthyretin amyloidosis (ATTR) and light chain amyloidosis (AL), which comprise >95% of CA cases. Very infrequently, in some patients ATTR and AL occur concurrently.

Progressive infiltrative cardiac involvement with cardiac symptoms often occurs years prior to diagnosis of hereditary transthyretin amyloidosis (hATTR). Investigators evaluated whether patients with hATTR signaled significant cardiovascular (CV) symptoms as well as healthcare utilization before being diagnosed.